JP Morgan Chase
FDMT icon

JP Morgan Chase’s 4D Molecular Therapeutics FDMT Stock Holding History

JP Morgan Chase’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-16,600
Closed -$529K – 7477
2024
Q1 		$529K Sell
16,600
-40,900
-71% -$1.04M ﹤0.01% 4757
2023
Q4 		$1.16M Buy
+57,500
New +$757K ﹤0.01% 4234

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

JP Morgan Chase's FDMT Position: Q1 2026 in Review

JP Morgan Chase increased its 4D Molecular Therapeutics (FDMT) stake by 49% in Q1 2026, buying an estimated $1.18M and bringing the position to 415,655 shares worth $3.56M. The position accounts for ﹤0.01% of the portfolio, ranked #3633.

JP Morgan Chase first reported a position in FDMT in Q1 2021 and has held it in 21 quarters since. The position peaked at $12.8M in Q1 2024. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • JP Morgan Chase held 415,655 shares of 4D Molecular Therapeutics worth $3.56M as of Q1 2026.
  • JP Morgan Chase bought 136,150 4D Molecular Therapeutics shares in Q1 2026, an estimated $1.18M.
  • 4D Molecular Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #3633 holding.
  • JP Morgan Chase first reported a position in 4D Molecular Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • JP Morgan Chase's 4D Molecular Therapeutics position peaked at $12.8M in Q1 2024.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.